Zoetis Inc. $ZTS Shares Bought by Delta Global Management LP

Delta Global Management LP raised its position in Zoetis Inc. (NYSE:ZTS) by 83.1% during the third quarter, HoldingsChannel reports. The firm owned 16,151 shares of the company’s stock after buying an additional 7,331 shares during the quarter. Delta Global Management LP’s holdings in Zoetis were worth $2,363,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of ZTS. Halbert Hargrove Global Advisors LLC increased its holdings in Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares during the last quarter. Financial Consulate Inc. purchased a new stake in Zoetis during the 3rd quarter worth about $39,000. SJS Investment Consulting Inc. boosted its position in shares of Zoetis by 1,606.3% during the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after acquiring an additional 257 shares in the last quarter. TruNorth Capital Management LLC acquired a new position in shares of Zoetis during the 3rd quarter worth about $42,000. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Zoetis in the 3rd quarter valued at about $46,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. UBS Group set a $136.00 price target on shares of Zoetis in a research note on Thursday, January 29th. HSBC set a $140.00 price objective on shares of Zoetis in a report on Wednesday, December 10th. Weiss Ratings upgraded shares of Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday. Finally, BTIG Research restated a “buy” rating and issued a $160.00 target price on shares of Zoetis in a report on Thursday, February 26th. Six analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Stock Up 2.2%

Shares of NYSE ZTS opened at $118.20 on Tuesday. The business has a 50-day moving average price of $125.12 and a 200 day moving average price of $131.33. The stock has a market cap of $49.90 billion, a PE ratio of 19.63, a price-to-earnings-growth ratio of 1.76 and a beta of 0.95. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a 52-week low of $114.47 and a 52-week high of $172.23.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same quarter in the previous year, the company posted $1.40 earnings per share. The firm’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s payout ratio is presently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.